Advertisement

Cost-effectiveness of Insulin Glargine Versus Sitagliptin in Insulin-naïve Patients With Type 2 Diabetes Mellitus

      Abstract

      Purpose

      In the EASIE (Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-Naïve Patients) trial, insulin glargine found a significant reduction in glycosylated hemoglobin compared with sitagliptin in patients with type 2 diabetes who are inadequately controlled with metformin. The objective of this study was to assess the cost-effectiveness of insulin glargine compared with sitagliptin in type 2 diabetes patients, from the perspective of the publicly funded Canadian health care system.

      Methods

      The IMS CORE Diabetes Model, a standard Markov structure and Monte Carlo simulation model, was used. The model used a lifetime horizon to capture the long-term complications associated with type 2 diabetes. The efficacy of insulin glargine and sitagliptin in terms of glycosylated hemoglobin reduction and corresponding rates of hypoglycemia were obtained from the EASIE trial. Health utility and cost data were obtained from recently published Canadian publications. Univariate and probabilistic sensitivity analyses were conducted.

      Findings

      In the lifetime base-case analysis, treatment with insulin glargine resulted in cost savings of $1434 CAD in 2012 and a gain of 0.08 quality-adjusted life years per patient. A probabilistic sensitivity analysis found the robustness of the base-case analysis, with 88% probability of insulin glargine being dominant (ie, cost savings and more quality-adjusted life years).

      Implications

      Insulin glargine is a clinically superior and cost-effective alternative to sitagliptin in patients with type 2 diabetes who are inadequately controlled with metformin.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Public Health Agency of Canada
        Diabetes in Canada: facts and figures from a public health perspective.
        Public Health Agency of Canada, Ottawa2011
        • International Diabetes Federation
        Diabetes Atlas.
        5th edition. International Diabetes Federation, Brussels2012
        • Sarwar N.
        • et al.
        Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies.
        Lancet. 2010; 375: 2215-2222
        • Booth G.L.
        • et al.
        Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study.
        Lancet. 2006; 368: 29-36
        • Canadian Agency for Drugs and Technologies in Health
        Optimal Use Recommendations for Second and Third-Line Therapy for Patients With Type 2 Diabetes.
        Canadian Agency for Drugs and Technologies in Health, Ottawa2013
        • Aschner P.
        • et al.
        Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial.
        Lancet. 2012; 379: 2262-2269
        • Palmer A.J.
        • et al.
        Validation of the CORE Diabetes Model against epidemiological and clinical studies.
        Curr Med Res Opin. 2004; 20: S27-S40
        • Palmer A.J.
        • et al.
        The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.
        Curr Med Res Opin. 2004; 20: S5-26
        • Canadian Agency for Drugs and Technologies in Health
        Guidelines for the Economic Evaluation of Health Technologies: Canada.
        3rd ed. 46. Canadian Agency for Drugs and Technologies in Health, Ottawa2006: vii (A1–A17)
        • Clarke P.M.
        • et al.
        A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68).
        Diabetologia. 2004; 47: 1747-1759
        • Cameron C.G.
        • Bennett H.A.
        Cost-effectiveness of insulin analogues for diabetes mellitus.
        CMAJ. 2009; 180: 400-407
        • Canadian Agency for Drugs and Technologies in Health
        Second-Line Pharmacotherapy for Type 2 Diabetes (Update).
        Canadian Agency for Drugs and Technologies in Health, Ottawa2013
        • Waugh N.
        • et al.
        Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
        Health Technol Assessment. 2010; 14: 1-248
        • Regie de l’assurance maladie du Quebec (RAMQ)
        List of Medications. RAMQ, Quebec2013
        • Klarenbach S.
        • et al.
        Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin.
        CMAJ. 2011; 183: E1213-E1220
        • O’Reilly D.
        • et al.
        Development of an Ontario Diabetes Economic Model (ODEM) and Application to a Multidisciplinary Primary Care Diabetes Management Program.
        McMaster University, Program for Assessment of Technology in Health (PATH), Hamilton2006
        • Manns B.
        • et al.
        Cost of Analysis of Ongoing Care of Patients with End-Stage Renal Disease: What are the Important Determinants?.
        Alberta Center for Health Services Utilization Research, Alberta2003
        • Guillermin A.L.
        • et al.
        Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis.
        J Med Econ. 2011; 14: 207-216
      1. OCCI, Ontario Case Costing Initiative. Last Updated: June 2012. Available at: http://www.occp.com/. Accessed July 8, 2012.

        • Consumer Price Index (CPI)
        2001 Basket Content, Health Care.
        Statistics Canada, Ottawa2013
        • O’Brien J.A.
        • Patrick A.R.
        • Caro J.J.
        Cost of managing complications resulting from type 2 diabetes mellitus in Canada.
        BMC Health Serv Res. 2003; 3: 7
        • Canadian Diabetes Association Clinical Practice Guidelines Expert Committe
        Canadian Diabetes Association 2008: clinical practice guidelines for the prevention and management of diabetes in Canada.
        Can J Diabetes. 2008; 32: s1-s201
        • American Diabetes Association
        Standards of medical care in diabetes—2009.
        Diabetes Care. 2009; 32: S13-S61
        • Gomes T.
        • et al.
        Blood Glucose Test Strip Use: Patterns, Costs and Potential Cost Reduction Associated with Reduced Testing.
        ICES, Ottawa2009
        • Currie C.J.
        • et al.
        Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes.
        Curr Med Res Opin. 2006; 22: 1523-1534
        • Canadian Agency for Drugs and Technologies in Health
        Third-Line Pharmacotherapy for Type 2 Diabetes (Update).
        Canadian Agency for Drugs and Technologies in Health, Ottawa2013
        • Canadian Agency for Drugs and Technologies in Health
        CADTH Optimal Use Report: Combination Use of Insulin and Incretins in Type 2 Diabetes.
        Canadian Agency for Drugs and Technologies in Health, Ottawa2013
      2. CADTH, Clopidogrel compared with other antiplatelet agents for secondary prevention of vascular events in adults undergoing percutaneous coronary intervention: clinical and cost-effectiveness analyses, 2010. http://www.cadth.ca/media/pdf/H2481_Clopidogrel_Percutaneous_Coronary_Intervention_tr_e.pdf

      3. Edmonton (AB): Alberta Health and Wellness. Health costing in Alberta: 2006 annual report. Edmonton (AB): Alberta Health and Wellness, 2010.